Brion W. Murray, Ph.D. work email
- Valid
- Valid
- Valid
Brion W. Murray, Ph.D. personal email
- Valid
Brion W. Murray, Ph.D. phone numbers
Leader in cancer biology and drug discovery with significant contributions to science and the clinic. Contributed to discovery or development of 7 FDA approved drugs. Leadership roles on teams that delivered 16 development candidates. Oncology Leader: President & cofounder of Riva Therapeutics (raised $33M), led both Lengo Therapeutics Research (NME in clinical investigation) and Turning Point Therapeutics cancer biology & translational research (2 NME’s, 2 combination trials, 4 drug discovery programs). Author of >90 publications and inventor on 17 patents. Senior editor, AACR journal Molecular Cancer Therapeutics. Research and LeadershipPresident, CSO and co-founder, Riva Therapeutics. Raised $33M to date. SVP, Research, Lengo Therapeuticso Co-discovered the CNS-penetrant, WT EGFR sparing EGFR Exon 20 insertion inhibitor LNG-451 (BLU-451) currently in clinical studies.VP, Cancer Biology & Translational Research at Turning Point Therapeuticso Created & led productive in vitro & in vivo pharmacology teams: TPX-0046 IND filing, TPX-0131 IND filing, 2 drug combination IND filings, 13 poster presentations, 2 manuscripts in preparation, and 4 patent filings. Top level researcher at Pfizer• Advisory team for the president of Pfizer R&D (Mikael Dolsten) (2017 – 2018)o Developed and implemented framework to accelerate drug discovery• Pfizer R&D Emerging Science Fund - selects opportunities for $1M/y funding (2018 – 2019)• Led multi-disciplinary Pfizer drug discovery team from concept through IND filing• Research leader, current team has 11 scientists, 4 with Ph.D. (2000 – 2019)• Contributed to discovery or development of FDA-approved drugs (axitinib, bosutinib, crizotinib, dacomitinib, palbociclib, sunitinib, paxlovid) (2009 – 2021)• Member of the Oncology Early Portfolio Leadership Team (2009 – 2011)• Member of the Oncology Research & Development Leadership Teams (2013 – 17)• Member of Oncology Project Review team (2017 – 2019)• Member of new target identification teams (>10 years)• Pharmacology leader for due diligence teams• Leader of multiple external collaborations• Facilitated acquisitions of Array Biopharma, SUGEN, Idun, and Nerviano• Scientific lead on Pfizer patent litigation teams (2016 – 2019)• Created the Pfizer Project Leader Workshop• Inventor on 17 patents or patent applications• Pfizer R&D Discovery Innovation Award (2006) and W.E. Upjohn Prizes (2015, 2016, 2017, 2018)
-
Senior EditorAacr JournalsSan Diego, Ca, Us
-
President, Cso & Co-FounderRiva Therapeutics May 2022 - PresentRiva Therapeutics is a next-generation, precision lethal oncology company resulting from a 3 year collaboration between the Broad Institute of Harvard and MIT and Novo Holdings. Our first-in-class targets have extensive genetic validation with clear molecular mechanisms that exploit synthetic lethality for cellular processes beyond DNA damage response for defined patient populations. Drug discovery operations are underway for multiple programs. We have raised $26.5M from Novo Ventures and Forward Equity Partners with a commitment from Novo Ventures for $12.5M more in 2024. -
Senior EditorMolecular Cancer Therapeutics Mar 2016 - PresentTucson, Arizona, UsMolecular Cancer Therapeutics is the AACR journal that strives to be the top choice for publishing the best science in the discovery and preclinical development of novel therapeutic agents for oncology, preclinical studies of approved therapeutics, mechanisms of drug action, mechanisms of drug resistance, biomarkers of drug response, novel models and technologies, and occasional drug toxicity mechanisms. -
FacultyFaculty Of 1000 Sep 2016 - PresentFaculty of 1000 - Chemical Biology of the Cell2018 Faculty Member of the Year for chemical biology. F1000Prime identifies and recommends important articles in biology and medical research publications. Articles are selected by a peer-nominated global 'Faculty' of the world's leading scientists and clinicians who then rate them and explain their importance. .
-
Associate Editor - Frontiers In Pharmacology, Frontiers In OncologyFrontiers Mar 2014 - PresentLausanne, Vaud, Ch -
Senior Vice PresidentLengo Therapeutics Oct 2021 - May 2022 -
Vice President, Cancer BiologyTurning Point Therapeutics Jun 2019 - Oct 2021San Diego, Ca, Us -
Member Board Of DirectorsMake-A-Wish Foundation Of San Diego Mar 2015 - Aug 2019San Diego, California, UsSince 1980, Make-A-Wish® has given hope, strength and joy to children with life-threatening medical conditions. Make-A-Wish® San Diego grants wishes to eligible children in San Diego and Imperial Counties. A wish come true helps children feel stronger, more energetic, more willing and able to battle their life-threatening medical conditions. For many, the wish marks a turning point in the fight against their illnesses. That is why wishes matter. -
Research Fellow (Senior/Executive Director Level Position)Pfizer Feb 2000 - Jun 2019New York, New York, UsSuccessful leader in cancer research & development recognized at Pfizer and in the research community. Examples of Leadership• Member of 12-person advisory to the president of Pfizer R&D (Mikael Dolsten) - led team in creating framework for drug discovery decision-making• Pfizer R&D Emerging Science Fund - selected external opportunities sized between $0.5-1MM/yr• Research group leader of team of 11 scientists with 4 having Ph.D.• Led multi-disciplinary drug discovery teams (20-30 FTEs) through IND filing. • Non-clinical leader of Sutent, Inlyta, & Torisel Development Teams• Active member of teams that delivered two drugs (axitinib, crizotinib).• Scientific expert on patent litigation teams • Pharmacology lead on drug due diligence teams• Led large multi-year, multi-site research oncology collaborations. • Member of the Oncology Early Portfolio Leadership Teams .• Member of the Oncology Target Selection Teams for >10 years.• Faculty of 1000, 2018 Faculty Member of the Year• Senior Editor, Molecular Cancer Therapeutics• Associate Editor, Frontiers in PharmacologyExamples of Scientific Contributions • Made many fundamental scientific discoveries published in top-tier journals. -Characterized CDK4/6 drug mechanism of action in patients (MCT 2016) -Discovered & patented therapy for drug resistance leukemia (Nature, 2015) -Developed framework for characterizing covalent drugs (PNAS 2014). -Discovered drug interaction with protein kinases (PNAS 2012). -Characterized PAK biology and first inhibitor to enter clinical trials (PNAS 2010). -Co-discovered the JNK inhibitor SP600125 (PNAS 2001). -Co-discovered the IkB kinases (Science 1997). -Defined model for explaining oncogenic effects of kinase activating mutations. -Identified a new mechanism for receptor tyrosine kinase regulation. -Showed that kinase autophosphorylation enhances catalytic “perfection”. -
Senior ScientistAgouron Pharmaceuticals 2001 - 2003Was acquired by Warner-Lambert which was acquired by Pfizer.
-
Senior Research ScientistCelgene Sep 1996 - Feb 2000Summit, New Jersey, UsResponsibilities included target discovery, target enzymology, assay development, HTS development, and molecular lead characterization. • Manager of non-Ph.D. researchers at Signal Pharmaceutics for over 2 years. • Research led to critical understanding of the enzymology of kinase-mediated signal transduction for multiple signaling pathways. • Discovered and characterized first potent cJun kinase inhibitor SP600125 (PNAS 2001). • Co-discovered the IB kinases (Science 1997). • Performed the first detailed enzymatic investigation of members of the newly discovered protein kinase family MAPK. • Designed a Zymark robotic system for molecular target-based screening of 50,000 tests per week. • Designed and developed the protein expression core facility. -
Post-Doctoral FellowThe Scripps Research Institute Aug 1994 - Sep 1996La Jolla, California, UsResearch with Professor Chi-Huey Wong was directed toward the study of glycosyl transfer enzyme mechanisms and the development of potent enzyme inhibitors. Published 8 articles in 2 years of work in Professor Wong’s laboratory. • The first detailed mechanistic studies of a human fucosyltransferase was performed in an effort to develop anti-cancer and anti-inflammatory agents. • Developed a new approach to glycosyltransferase inhibition that utilized fluorinated nucleotide-sugars as mechanism-based inhibitors. • Developed a new class of sugar analog, cyclic guanidino sugar, as both a potent inhibitor and mechanistic probe of glycosyl transfer enzymes. -
Graduate AssistantUniversity Of Maryland 1989 - 1994College Park, Md, UsResearch with Professor John W. Kozarich focused on the mechanistic characterization of glycyl radical formation on pyruvate formate-lyase by its requisite activating enzyme. • Discovered a direct, stereospecific, rate-limiting hydrogen abstraction from a glycyl residue in the protein-protein interaction. • Identified the role of S-adenosylmethionine in radical biosynthesis. • Studied the metal cofactor of the enzymatic radical forming reaction both kinetically and spectrometrically. -
Research ChemistAmerican Cyanamid Chemical Co Jan 1987 - Jan 1989Developed and characterized aliphatic isocyanate polymer crosslinking agents. Investigated UV absorbing compounds for their ability to protect polymer systems
-
Undergraduate Research AssistantUniversity Of North Carolina Jan 1986 - Jan 1987Raleigh, North Carolina, UsInvestigated copper deposition in the laboratory of Professor Richard P. Buck in collaboration with IBM. Electrochemically characterized absorption enhancing compounds for their ability to promote uniform monolayer formation.
Brion W. Murray, Ph.D. Skills
Brion W. Murray, Ph.D. Education Details
-
Scripps ResearchBiochemistry And Synthetic Chemistry -
University Of MarylandBiochemistry
-
University Of North Carolina At Chapel HillChemistry
Frequently Asked Questions about Brion W. Murray, Ph.D.
What company does Brion W. Murray, Ph.D. work for?
Brion W. Murray, Ph.D. works for Aacr Journals
What is Brion W. Murray, Ph.D.'s role at the current company?
Brion W. Murray, Ph.D.'s current role is Senior Editor.
What is Brion W. Murray, Ph.D.'s email address?
Brion W. Murray, Ph.D.'s email address is br****@****zer.com
What is Brion W. Murray, Ph.D.'s direct phone number?
Brion W. Murray, Ph.D.'s direct phone number is +121257*****
What schools did Brion W. Murray, Ph.D. attend?
Brion W. Murray, Ph.D. attended Scripps Research, University Of Maryland, University Of North Carolina At Chapel Hill.
What skills is Brion W. Murray, Ph.D. known for?
Brion W. Murray, Ph.D. has skills like Drug Discovery, Biochemistry, Assay Development, Drug Development, Protein Chemistry, Cell Biology, Pharmaceutical Industry, Pharmacology, Molecular Biology, Cancer, Cell Signaling, Oncology.
Free Chrome Extension
Find emails, phones & company data instantly
Aero Online
Your AI prospecting assistant
Select data to include:
0 records × $0.02 per record
Download 750 million emails and 100 million phone numbers
Access emails and phone numbers of over 750 million business users. Instantly download verified profiles using 20+ filters, including location, job title, company, function, and industry.
Start your free trial